Last May, researchers at a pharmaceutical conference in Orlando, Florida had tears in their eyes as they were given a standing ovation from an audience of medical specialists. The emotion was sparked by early reports from researchers on a substantial medical trial which convinced them they were witnessing a fundamental breakthrough in the treatment of breast cancer.
Last Thursday, the results of trials were mapped out in full. And hopes appeared to be fully vindicated. The New England Journal of Medicine (NEJM) published conclusions from the first trials of Herceptin.
It reveals "a dramatic and perhaps permanent perturbation in the natural history of the disease, maybe even a cure." Those same researchers concluded that women treated with Herceptin had a 46 percent reduced risk of their breast cancer returning.
For Roche the news could be lucrative. The Swiss giant will own the drug and have it under patent for 20 years. Herceptin, if it continues through the trial process and gets regulatory approval, could boost Roche's annual revenue by a stunning ?2.5 billion, according to analysts, and will be a total vindication of its decision to invest in the biotechnology sector.
Before the trials had even been completed, Herceptin sales grew 58 percent to ?280 million. Herceptin treats an aggressive form of breast cancer known as Her-2 positive.
bow to pressure
In the UK, Health Secretary Patricia Hewitt said the drug would be available on the tax-funded National Health Service (NHS). She bowed to pressure after Barbara Clark, a 49-year-old nurse, threatened to take her local health authority to the European Court of Human Rights if it did not prescribe her the drug.
Hewitt's concession will benefit 5,000 of the 35,000 women with breast cancer in the UK.
However, according to the Herceptin Web site "administration can result in the development of certain heart problems, including congestive heart failure. Severe allergic reactions, infusion reactions, and lung problems have been observed."
But Denise Anderson, head of healthcare at Kepler Equities, said: "Roche is providing innovation. I could not care less about the hundreds of anti high-blood pressure products. This drug looks like it will literally give women a new lease of life."
The trials reported in the NEJM involved 3,000 women in the US and 5,000 women in 39 other countries who were randomly allocated treatment with Herceptin after chemotherapy.
As Roche thrives many of the world's other major drug firms are suffering. Pfizer, the world's biggest, is struggling with the loss of patents on key treatments and a healthcare scare linked to the arthritis drug Celebrex. The result saw a 52 percent slump in quarterly profits announced last week.
Pfizer has been criticized for a failure to produce new blockbuster drugs from its research and development unit despite an annual US$7 billion budget.
Meanwhile GlaxoSmithKline has struggled to integrate its US and UK managements after its mega-merger five years ago.
Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) halted shipments to a customer this month after its semiconductors were sent to China’s Huawei Technologies Co (華為), potentially breaching US sanctions, a government official said. The US slapped sanctions on Huawei in 2019, and expanded them the following year, over fears its technology could be used for Beijing’s espionage operations. The restrictions prevent TSMC from selling semiconductors to Huawei. However, TSMC discovered on Oct. 11 that chips made for a “specific customer” had ended up with the Chinese company, a Taiwanese official with knowledge of the incident said on the condition of anonymity. TSMC “immediately activated
US SANCTIONS: The Taiwan tech giant has ended all shipments to China-based Sophgo Technologies after one of their chips was discovered in a Huawei phone Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) suspended shipments to China-based chip designer Sophgo Technologies Ltd (算能科技) after a chip it made was found on a Huawei Technologies Co (華為) artificial intelligence (AI) processor, according to two people familiar with the matter. Sophgo had ordered chips from TSMC that matched the one found on Huawei’s Ascend 910B, the people said. Huawei is restricted from buying the technology to protect US national security. Reuters could not determine how the chip ended up on the Huawei product. Sophgo said in a statement on its Web site yesterday that it was in compliance with all laws
TECH TITANS: Nvidia briefly overtook Apple again on Friday after becoming the world’s largest company for a short period in June, as Microsoft fell to third place Nvidia Corp dethroned Apple Inc as the world’s most valuable company on Friday following a record-setting rally in the stock, powered by insatiable demand for its specialized artificial intelligence (AI) chips. Nvidia’s stock market value briefly touched US$3.53 trillion, slightly above Apple’s US$3.52 trillion, London Stock Exchange Group data showed. Nvidia ended the day up 0.8 percent, with a market value of US$3.47 trillion, while Apple’s shares rose 0.4 percent, valuing the iPhone maker at US$3.52 trillion. In June, Nvidia briefly became the world’s most valuable company before it was overtaken by Microsoft Corp and Apple. The tech trio’s market capitalizations have been
Shares of Starlux Airlines Co (星宇航空) surged more than 53 percent on its debut on the Taiwan stock exchange yesterday. Starlux shares closed up 53.75 percent at NT$30.75 from its initial public offering price of NT$20 after retreating in late trading from a 60 percent rise. China Airlines Ltd (CAL, 中華航空) rose 0.90 percent to close at NT$22.35, while EVA Airways Corp (長榮航空) gained 0.40 percent to close at NT$37.70. In Taiwan, a newly listed stock is allowed to go beyond the 10 percent maximum increase or decline in its first five trading sessions. At the listing ceremony, Starlux chairman Chang Kuo-wei (張國煒) said
RSS